A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer
This is a Phase I Dose-Escalation Study of BMS641988 in Patients with Castration-Resistant Prostate Cancer.
Prostate Cancer
DRUG: AR Antagonist (BMS-641988)
To assess safety and tolerability and to identify a dose for Phase II evaluation, during the dose escalation phase
To evaluate pharmacokinetics, throughout the study|To describe preliminary evidence of anit-tumor activity, throughout the study
This is a Phase I Dose-Escalation Study of BMS641988 in Patients with Castration-Resistant Prostate Cancer.